| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.4M | — | +60.3% |
| SG&A Expense | $1.7M | — | +38.8% |
| Operating Income | -$3.1M | — | -47.6% |
| Net Income | -$3.0M | — | -46.7% |
| EPS (Basic) | -$2.71 | — | -28.4% |
| EPS (Diluted) | -$2.71 | — | -28.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $14.1M | +31.9% | +281.0% |
| Current Assets | $14.2M | +31.4% | +261.7% |
| Total Assets | $15.0M | +29.9% | +278.9% |
| Current Liabilities | $1.4M | -29.1% | +30.1% |
| Total Liabilities | $2.1M | -24.5% | +88.6% |
| Stockholders' Equity | $13.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.2M | — | -15.0% |
| Capital Expenditures | $72K | — | — |
| Investing Cash Flow | -$72K | — | — |
| Financing Cash Flow | $6.7M | — | — |
| Free Cash Flow | -$3.3M | — | — |
| +350.9% |